NCT05212454View on ClinicalTrials.gov

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2029

Conditions
Breast CancerChemotherapy Effect
Interventions
DRUG

Capecitabine

capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.

Trial Locations (1)

Unknown

RECRUITING

the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER